In conclusion, we showed that the PBIS scoring system using serum IL-2 and IL-12 levels in addition to the NLR and CRP analyzed at the baseline of AB treatment in patients with HCC can be a competent prognostic and predictive biomarker for clinical outcomes. The gene discussed is CRP; the disease is hepatocellular carcinoma.